Universitätsklinikum Magdeburg AöR

Magdeburg 39120

2 studies enrolling now · 8 studies all time

What they study most

Advanced Hepatocellular Carcinoma (HCC), Atrial Fibrillation, Breast Neoplasms, CIDP, CIDP (Chronic Inflammatory Demyelinating Polyradiculoneuropathy), Chronic Inflammatory Demyelinating Polyradiculoneuropathy, Heart Failure, Kidney Disease, Chronic, Percutaneous Coronary Intervention, Secondary Prevention, Stroke, Stroke, Ischemic

Studies at this site

• EASi-KIDNEY™ (The Studies of Heart & Kidney Protection With BI 690517 in Combination With Empagliflozin) — Recruiting now
• Real-World Efgartigimod Effectiveness in CIDP: A Prospective Study — Recruiting now
• A Randomized, Placebo-controlled, Double-blind Phase 2 Study With OSI-906 in Patients With Advanced HCC — Stopped early
• COMPLETE: International Acute Ischemic Stroke Registry With the Penumbra System Aspiration Including the 3D Revascularization Device — Completed
• This Study Tests Empagliflozin in Patients With Chronic Heart Failure With Preserved Ejection Fraction (HFpEF). The Study Looks at How Far Patients Can Walk in 6 Minutes and at Their Heart Failure Symptoms. — Completed
• Dabigatran Etexilate for Secondary Stroke Prevention in Patients With Embolic Stroke of Undetermined Source (RE-SPECT ESUS) — Completed
• LUX-Breast 1: BIBW 2992 (Afatinib) in HER2-positive Metastatic Breast Cancer Patients After One Prior Herceptin Treatment — Completed
• Evaluation of Dual Therapy With Dabigatran vs. Triple Therapy With Warfarin in Patients With AF That Undergo a PCI With Stenting (REDUAL-PCI) — Completed